Abstract
Uric acid (UA) is the end product of purine nucleotide metabolism in the human body. Hyperuricemia is an abnormally high level of UA in the blood and may result in arthritis and gout. The prevalence of hyperuricemia has been increasing globally. Epidemiological studies have shown that UA levels are positively correlated with cardiovascular diseases, including hypertension, atherosclerosis, atrial fibrillation (AF), and heart failure (HF). Hyperuricemia promotes the occurrence and development of cardiovascular diseases by regulating molecular signals, such as inflammatory response, oxidative stress, insulin resistance/diabetes, endoplasmic reticulum stress, and endothelial dysfunction. Despite extensive research, the underlying molecular mechanisms are still unclear. Allopurinol, a xanthine oxidase (XO) inhibitor, has been shown to improve cardiovascular outcomes in patients with HF, coronary heart disease (CHD), type 2 diabetes (T2D), and left ventricular hypertrophy (LVH). Whether febuxostat, another XO inhibitor, can improve cardiovascular outcomes as well as allopurinol remains controversial. Furthermore, it is also not clear whether UA-lowering treatment (ULT) can benefit patients with asymptomatic hyperuricemia. In this review, we focus on the latest cellular and molecular findings of cardiovascular disease associated with hyperuricemia and clinical data about the efficacy of ULT in patients with cardiovascular disease.
Introduction
Uric acid (UA) is the end product of purine metabolism in higher animals, such as humans and great apes. Under physiological conditions, UA synthesis and excretion are balanced in the body. Once this balance is disturbed, it leads to hyperuricemia. Normally, male UA levels greater than 7 mg/dL or female UA levels greater than 6 mg/dL are considered to be hyperuricemia (). However, Virdis et al. confirmed that the threshold of UA level increased total mortality (4.7 mg/dL) and cardiovascular mortality (5.6 mg/dL) risk, which was significantly lower than clinical diagnostic criteria (Virdis et al., 2020). With increasingly unhealthy lifestyles, the incidence of hyperuricemia is increasing, and it has become the “fourth highest” after hypertension, hyperglycemia, and hyperlipidemia. It is estimated that the total number of patients with hyperuricemia was 170 million in China () and 32.5 million in the United States (Singh et al., 2019). Large-scale clinical studies on the relationship between serum uric acid (sUA) and cardiovascular diseases started from the Framingham Heart Study in the 1980s, the results of which indicate that UA does not have a causal role in the development of coronary heart disease (CHD), death from cardiovascular disease or all causes (). Recent epidemiological studies show that hyperuricemia may be involved in hypertension, diabetes, atherosclerosis, chronic kidney disease, and atrial fibrillation (AF) as well as the occurrence of cardiovascular events (; ; ; ; Kuwabara et al., 2018b; Maruhashi et al., 2018). Experimental studies show that hyperuricemia promotes the occurrence and development of cardiovascular diseases by regulating molecular signals, such as inflammatory response (Xiao et al., 2015; ; Lu et al., 2019), oxidative stress (Li et al., 2018), insulin resistance (Zhi et al., 2016), endothelial dysfunction (Maruhashi et al., 2018), and endoplasmic reticulum stress (Li P. et al., 2016; Yan et al., 2018).
An increasing number of clinical studies show that allopurinol can improve cardiovascular outcomes in patients with heart failure (HF), CHD, type 2 diabetes (T2D), and left ventricular hypertrophy (LVH) (; ; ; Noman et al., 2010; Rekhraj et al., 2013; Szwejkowski et al., 2013). Compared to allopurinol, whether febuxostat improves cardiovascular outcomes remains controversial (White et al., 2018; Zhang et al., 2018; ). Furthermore, whether UA-lowering treatment (ULT) is beneficial to patients with asymptomatic hyperuricemia is uncertain because these patients are often associated with a variety of risk factors (such as old age, chronic kidney disease, cardiovascular disease, obesity, metabolic syndrome, alcohol, or smoking habits, etc.) but without identified diseases. In addition, UA is an effective antioxidant in cardiovascular and neurodegenerative diseases (), making the relationship between UA and cardiovascular disease more complicated.
This review focuses on the underlying mechanisms of cardiovascular disease associated with hyperuricemia and the efficacy of ULT in patients with cardiovascular disease.
UA and its Related Molecular Mechanism
UA and Oxidative Stress
UA is the final product of dietary purines. Existing evidence suggests that UA has a dual-face role in some cardiovascular and cerebrovascular diseases. On the one hand, UA has antioxidant activity and can scavenge reactive oxygen species (ROS). As one of the main endogenous antioxidants in the human body, UA contributes up to 60% of the plasma antioxidant capacity, which can protect cells from oxidative stress (; Sautin and Johnson, 2008). The molecular mechanism of the antioxidation of UA are as follows: 1. It reacts directly with hydroxyl radicals, peroxynitrite, nitric oxide, and hydrogen peroxide, etc., forming stable intermediates (); 2. it cooperates with superoxide dismutase to scavenge oxygen radicals (Waring et al., 2001); 3. it chelates with metal ions (); and 4. it inhibits the peroxynitrite-induced protein nitrification, protein, and lipid peroxidation (Whiteman et al., 2002). On the other hand, UA can promote oxidation activity in cells, which may be related to oxygen free radicals produced by ROS. The pro-oxidation mechanisms of UA include 1. reducing the production of nitric oxide in arterial endothelial cells and inhibiting vasodilation (Papezikova et al., 2013); 2. inhibiting the synthesis of adiponectin in adipocytes; 3. damaging the tricarboxylic acid cycle and fatty acid β oxidation; 4. activating the renin-angiotensin system, stimulating the proliferation of vascular smooth muscle cells and the production of angiotensin II (Ang II) (); and 5. generating a chronic inflammatory reaction (). The dual effects of UA on anti- and pro-oxidants may be closely related to the xanthine oxidase (XO) activity in circulation. Several studies have associated the involvement of XO activity, a source of UA and ROS, to pro-oxidative and pro-inflammatory effects during pathological conditions (; ; ).
In recent years, a lot of progress has been made on the relationship between UA and oxidative stress and its molecular mechanism. The physiological concentration of UA decreased oxidative stress–induced malondialdehyde and protein carbonyl contents, promoted superoxide dismutase (SOD) activity, and inhibited the formation of ROS in chicken embryo cardiomyocytes (Sun et al., 2017). The underlying mechanism was the NF-E2-related factor 2 (Nrf2) signal pathway (Sun et al., 2017). In contrast, treated with a high concentration of UA (1200 µM), the Nrf2 signaling pathway was inhibited, malondialdehyde and protein carbonyl contents were increased, and SOD activity was decreased (Figure 1A) (Sun et al., 2017). Our research team found that high UA inhibited the viability of H9c2 cardiomyocytes and increased the production of ROS (Li et al., 2018). Pretreatment with ROS scavenger (N-acetyl-L-cysteine) and extracellular signal-regulated kinase (ERK) inhibitor (PD98059) reversed the decrease of cell viability induced by high UA (Li et al., 2018). Further studies show that high UA-induced ROS may be closely related to ERK/p38 activation and phosphatidylinositol 3-kinase (PI3K)/Akt inhibition (Figure 1A) (Li et al., 2018). In addition, UA has a neuroprotective effect on dopaminergic neurons in Parkinson's disease mice, which may be related to Nrf2-ARE signal activation, reduction of oxidative damage, and neuroinflammation ().
Figure 1
In short, previous studies have confirmed that UA has both antioxidant and pro-oxidant effects in vivo. This dual effect of UA has also been confirmed in cardiomyocytes. The latest experimental studies demonstrate that the antioxidation of UA may be involved in regulating the Nrf2-ARE, ERK/p38, and PI3K/Akt signaling pathways.
UA and Inflammatory Response
UA has been a focus of research not only for its role in oxidative stress, but also for its relation to various inflammatory diseases. Atherosclerosis is a chronic immuno-inflammatory cardiovascular disease. A large body of evidence suggests that elevated UA levels are strongly associated with the occurrence and development of atherosclerosis. High intracellular UA concentrations promote the expression of inflammatory markers, such as nuclear factor κB (NF-κB), growth factors, vasoconstrictive substances (Ang II, thromboxane, and endothelin-1), and chemokines via activating mitogen-activated protein kinases (MAPK) (Figure 2) (Xiao et al., 2015; ). Additionally, hyperuricemia promoted macrophage M1/M2 polarization, which could be reversed by ULT (). In the development of obesity and cardiorenal disease, UA tends to enhance the pro-inflammatory response of M1 and inhibit the anti-inflammatory response of M2 (). M1 macrophages secrete inflammatory cytokines, leading to insulin resistance and cardiac dysfunction (). On the contrary, M2 macrophages secrete interleukin-10 (IL-10), which inhibits cardiomyocyte hypertrophy and myocardial fibrosis (Figure 2) (). Furthermore, in a randomized, open, parallel-controlled study involving 176 patients with T2D and asymptomatic hyperuricemia, allopurinol effectively lowered sUA, improved insulin resistance, reduced serum high-sensitivity C-reactive protein (hs-CRP) level, decreased carotid intima-media thickness, and ameliorated the exacerbation of atherosclerosis (Liu et al., 2015).
Figure 2
The activation of inflammasomes plays a critical role in a variety of chronic inflammatory diseases. Recently, many studies have found that sUA can effectively activate inflammasomes in the cardiovascular system. The continuous activation of inflammasomes aggravates the inflammatory response and damages the cardiovascular system. Studies by Wang et al. report that UA can activate nod-like receptor protein 3 (NLRP3) inflammasomes and damage mitochondria, resulting in cellular damage of H9c2 cells (Wang et al., 2018). In addition, several studies also show that UA activates the NLRP3 inflammasome and induces interleukin-1β (IL-1β) release in a variety of cells, including monocytes, macrophages, vascular smooth muscle cells, and endothelial cells (Martinon et al., 2006; Matias et al., 2015; ; ; Li et al., 2019; Yin et al., 2019). The molecular mechanism of UA-induced NLRP3/IL-1 β activation is through NF-κB activation and mitochondrial ROS (mROS) (Figure 2). Consistent with the latest research published by Kimura et al., UA promotes the secretion of IL-1β mediated by NLRP3 inflammasomes via regulating the AMP-activated protein kinase (AMPK)-mammalian target of rapamycin (mTOR) mROS and hypoxia-inducible factor-1α (HIF-1α) pathway in human peripheral blood mononuclear cells (Figure 2) (). In mice treated with uricase gene transfer and XO inhibitor, however, the decrease of UA level promoted the activation of AMPK, and the formation of atherosclerotic plaque was inhibited ().
In conclusion, UA has been shown to promote inflammation in a variety of cells. Hyperuricemia can promote the development of atherosclerosis by regulating inflammatory signal pathways, such as NLRP3-inflammasomes, macrophage M1/M2 polarization, and hs-CRP, and ULT can significantly reverse the formation of atherosclerotic plaques. Inhibition of UA-induced NLRP3 inflammasome activation may be a new therapeutic target for atherosclerosis.
UA and Insulin Resistance/Diabetes
Insulin resistance is closely related to diabetes, obesity, hyperlipidemia, hypertension, hyperuricemia, and other metabolic disorders. Current studies confirm that oxidative stress and inflammation may be the pathophysiological basis of insulin resistance. Hyperuricemia can promote oxidative stress in many cell lines. The rise of ROS level can induce insulin resistance. Oxidative stress may be the cause of insulin resistance–related cardiovascular complications because overgenerated ROS and insulin resistance may lead to cardiac dysfunction (Ritchie, 2009). Our team's research shows that high UA can increase ROS production and inhibit insulin-induced glucose uptake in H9c2 and primary cardiomyocytes, and N-acetyl-L-cysteine pretreatment can reverse the inhibitory effect of high UA on glucose uptake (Zhi et al., 2016). The molecular mechanism may be that high UA increases the phosphorylation of insulin receptor substrate 1 (IRS1) and inhibits the phosphorylation of Akt, which was blocked by N-acetyl-L-cysteine (Figure 1A) (Zhi et al., 2016). Hence, high UA can induce insulin resistance in cardiomyocytes in vitro and in vivo.
Clinical studies have shown a link between hyperuricemia and diabetes (; van der Schaft et al., 2017); however, it is controversial whether hyperuricemia plays a causal role in diabetes. Recently, Lu et al. confirmed that there is no causal relationship between hyperuricemia and diabetes (Lu et al., 2020). High UA accelerates but does not cause diabetes because UA itself is insufficient to induce diabetes although it can damage glucose tolerance, leading to insulin resistance (Lu et al., 2020). Although the mechanism of high UA–induced myocardial insulin resistance has not been fully elucidated, it might be a novel potential mechanism of hyperuricemic-related cardiovascular disease.
UA and Endoplasmic Reticulum Stress
Cardiomyocyte apoptosis is one of the pathogeneses of myocardial anatomical reconstruction. Oxidative stress and endoplasmic reticulum stress are the key factors promoting apoptosis, which are involved in the pathogenesis of many diseases, including cardiovascular diseases. UA triggers oxidative stress and endoplasmic reticulum stress to signal the network to induce endothelial dysfunction via activating the protein kinase C (PKC) pathway in human umbilical vein endothelial cells (HUVECs) (Li P. et al., 2016). The latest research also demonstrates that UA can induce cardiomyocyte apoptosis in vitro and in vivo, and its molecular mechanism might be through the activation of calpain-1 and the endoplasmic reticulum stress signaling pathway (Figure 1B) (Yan et al., 2018). So far, the studies on UA-induced endoplasmic reticulum stress is scarce, but it is certain that there will be more research to clarify the relationship between the two in the future.
UA and Endothelial Dysfunction
Endothelial cells secrete a variety of vasoactive substances, including vasodilators (nitric oxide, prostaglandin I2, endothelium-derived hyperpolarizing factor, etc.) and vasoconstrictors (endothelin-1, thrombin A2, Ang II, etc.) (Vane et al., 1990; Maruhashi et al., 2018). Vasodilator nitric oxide plays a key role in the development of atherosclerosis. The increase of UA level in cells directly combined with nitric oxide, which resulted in the decrease of nitric oxide bioavailability and the increase of peroxynitrite (ONOO–) (Maruhashi et al., 2018). ONOO– is a strong oxidant, which can cause DNA damage, cell death, and lipid peroxidation (Maruhashi et al., 2018). In addition, Li et al. found that high UA-induced HUVEC apoptosis and endothelial dysfunction is through PKC-dependent endothelial nitric oxide synthase (eNOS) phosphorylation and endoplasmic reticulum stress, reducing eNOS activity and nitric oxide production (Li P. et al., 2016). Furthermore, a recent study also indicates that high UA inhibits eNOS expression and nitric oxide production in HUVECs, increases high mobility group box chromosomal protein 1 (HMGB1)/receptor for advanced glycation end products (RAGE) expression, activated NF-κB, and increased the inflammatory cytokine levels (). All these results provide new insight into the mechanisms of UA-induced endothelial dysfunction (Figure 1B).
Endothelial dysfunction plays a critical role in the development and progression of atherosclerosis, leading to serious cardiovascular events. Experimental studies show that high UA aggravates the inflammation response and oxidative stress and, thus, leads to endothelial dysfunction (Xiao et al., 2015; ; Li et al., 2018; Lu et al., 2019). Additionally, hyperuricemia-induced endothelial dysfunction is also confirmed in many clinical studies (Mercuro et al., 2004; ; ; Tomiyama et al., 2011; Sincer et al., 2014). All these experiments and clinical studies show that UA is not only a biomarker of cardiovascular risk, but also a causal risk factor of endothelial dysfunction (). Notably, Borgi et al. found that ULT was not associated with endothelial dysfunction improvement in nonhypertensive, overweight/obese individuals (). Therefore, the hypothesis of the causal relationship between UA and endothelial dysfunction needs further study.
UA and Cardiovascular Disease
UA and Hypertension
Elevated sUA is strongly associated with hypertension, but the mechanism is not clear. Hyperinsulinemia induced by insulin resistance enhances renal sodium reabsorption, which may lead to hypertension (; ). Endothelial dysfunction caused by oxidative stress also plays a key role in the development of hypertension, kidney disease, and cardiovascular disease (Mortada, 2017). Studies have shown that UA significantly increased the production of ROS and Ang II in human endothelial cells (Yu et al., 2010).
In recent years, numerous studies have demonstrated the link between sUA and hypertension. In a prospective randomized study of 5748 healthy adolescents, a 10-year follow-up showed that elevated sUA was closely associated with hypertension and metabolic syndrome (Sun et al., 2015) Recently, a retrospective cohort study of 3584 prehypertensive patients also showed that increased sUA was a strong risk marker for developing hypertension from prehypertension (Kuwabara et al., 2018b). In another large-scale meta-analysis of 55,607 subjects in 18 prospective cohort studies, it was found that, for every 1 mg/dl increase in sUA, the incidence of hypertension increased by 13% (). This result is consistent with the result recently published by Bjornstad et al. that higher baseline sUA independently increased the risk of incident hypertension (hazard ratio 1.19, per 1 mg/dL increase in sUA) (). Arterial stiffness and inflammation may be involved in the risk of development of hypertension associated with hyperuricemia (Tomiyama et al., 2018), but this result is inconsistent with Cicero et al., who show that sUA is significantly correlated to hypertension and carotid intima–media thickness but not to aortic stiffness (). Interestingly, recently published experimental studies do not seem to be consistent with the above epidemiological and clinical studies. Chen et al. show that UA level is not positively correlated with blood pressure (BP) in people with early Parkinson's disease (). In addition, the increase of UA level was also not related to the change of BP, cardiac morphology, and heart dysfunction in a Uricase/Uox knockout male mouse model ().
Likewise, this close relationship between UA and hypertension also exists in pregnant women. The level of sUA in pregnant women is higher than that in normal, nonpregnant women, and the incidence of hypertensive disorders of pregnancy is significantly increased in pregnant women with hyperuricemia (Sakr et al., 2020). The mechanisms of increased UA level during pregnancy may be related to the decrease of estrogen concentration, the increase of high purine food intake, and the increase of XO activity. Increased UA level strongly correlated to the severity of preeclampsia and higher risk of gout in later life (Wang I. K. et al., 2016; ).
In conclusion, sUA is closely correlated with BP, but a consistent effect has not been observed in ananimal model and human studies. Fortunately, the recent published results by Johnson et al. give us an answer. After treatment with pegloticase, sUA remained at a low level in hyperuricemia patients, and its systolic and diastolic BP decreased significantly, which was independent of changes in renal function (). These findings give us reasons to believe that there may be a causal link between hyperuricemia and hypertension (Figure 3A).
Figure 3
UA and CHD
Atherosclerosis is the most common cardiovascular disease with the highest morbidity and mortality. The possible mechanisms of UA induced CHD may include the following (Wu et al., 2012): 1. Vascular endothelial damage of large and micro vessels: urate is easy to deposit in the vascular wall and stimulate the proliferation of vascular smooth muscle cells; high UA can activate the renin-angiotensin system, inhibit nitric oxide production, and induce endothelial cell dysfunction (; Sautin and Johnson, 2008; Papezikova et al., 2013). 2. UA can cause platelet activation, adhesion, and aggregation. 3. Hyperuricemia participates in the production of many inflammatory mediators (such as interleukin, C-reactive protein, etc.) (). 4. Hyperuricemia can increase the production of oxygen free radicals, which can cause low-density lipoprotein peroxidation, damage endothelial cells, promote vascular smooth muscle and intimal hyperplasia, etc. (Whiteman et al., 2002). 5. High UA can directly cause low-density lipoprotein oxidation (Wu et al., 2012).
A prospective cohort study of 457,915 subjects without cardiovascular disease found that UA concentrations >7.0 mg/dl significantly increased the risk of CHD in the general population (mainly adult women) (). Another study suggested that sUA > 8 mg/dl was independently associated with three vessel diseases: coronary artery, HF, and LV enlargement in Chinese patients with early-onset CHD (). In a meta-analysis of 12,677 subjects, elevated sUA level was found to be significantly associated with poor prognosis (all-cause mortality, cardiovascular mortality, and hospitalization for HF) in patients with LV dysfunction, HF, or both after myocardial infarction (MI) (von Lueder et al., 2015). sUA can be used as a low-cost and widely used biomarker to evaluate the clinical risk stratification of patients with MI. According to a systematic review of 29 prospective cohort studies involving 958,410 subjects, for every 1 mg/dl increase in sUA level, the mortality rate of CHD was 1.02 in men and 2.44 in women (Li M. et al., 2016). This result is consistent with the result published by Wang et al. that increased sUA levels are closely related to the risk of cardiovascular and all-cause mortality in people with suspected or definite CHD (Wang R. et al., 2016). For every 1 mg/dl increase in sUA, cardiovascular and all-cause mortality increased by 12% and 20%, respectively (Wang R. et al., 2016).
Although many clinical studies confirm that elevated sUA levels are strongly and independently associated with the occurrence and development of coronary atherosclerosis, the severity of coronary artery lesions and cardiovascular and all-cause mortality, the molecular mechanism of UA promoting atherosclerosis is still unclear. Plaque morphology, endothelial dysfunction, oxidative stress, and inflammation play a critical role in the development and progression of atherosclerosis, leading to serious cardiovascular events (Prasad et al., 2017). Optical coherence tomography showed a significant increase in plaque rupture in patients with sUA > 8.0 mg/dl (). Recently, Kimura et al. demonstrated that UA promotes the secretion of IL-1β mediated by NLRP3 inflammasomes via regulating the AMPK-mTOR mROS and HIF-1α pathway in human peripheral blood mononuclear cells (). In mice treated with uricase gene transfer and XO inhibitor, however, the decrease of UA level promoted the activation of AMPK and inhibited the formation of atherosclerotic plaque (). In addition, the coronary artery calcium (CAC) score can reflect total atherosclerotic burden, which is another effective index to predict future CVD events. Jun et al. evaluated the correlation between CAC and sUA in 9297 subjects by multidetector CT (). The results show that sUA level is an independent predictor for development of moderate CAC in generally healthy adults ().
In brief, hyperuricemia is a potential risk factor for CHD. The elevated sUA may lead to endothelial dysfunction through inflammation and oxidative stress and the formation of unstable lipid plaque in the coronary artery, which eventually leads to the occurrence of atherosclerosis. Therefore, lowering the level of UA is crucial in the prevention and treatment of CHD (Figure 3B).
UA and AF
AF is the most common heart rhythm disorder, and its major risk factors include advanced age, hypertension, obesity, diabetes, HF, valvular heart disease, and MI. In recent years, numerous clinical studies have confirmed that hyperuricemia is associated with AF after adjusting for various cardiovascular risk factors, and the correlation is stronger in women than in men (Liang et al., 2016; Zhang et al., 2016; ; ; Mantovani et al., 2018; Pak et al., 2018; ; Lin et al., 2019). The bases for sex-related differences in high UA and AF or CHD remains unknown. High UA has been associated with endothelial dysfunction in postmenopausal women, suggesting that high UA could be an independent risk factor for cardiovascular disease, including AF and CHD, particularly among postmenopausal women (Maruhashi et al., 2013; Lin et al., 2019).
In addition, sUA was also an independent risk factor of LA thrombus in patients with nonvalvular AF or with mitral stenosis in sinus rhythm (Tang et al., 2014; Ozturk et al., 2015). UA level is negatively correlated with the systolic function of the lower left atrial appendage (LAA) (). It can provide prognostic information for long-term thromboembolic events in patients with AF (). There are also studies suggesting that hyperuricemia is associated with an increased risk of AF recurrence after catheter ablation (). In a recent meta-analysis involving 1298 patients with AF, however, elevated sUA was not associated with the risk of AF recurrence after catheter ablation (Zhao et al., 2016).
The mechanisms of high UA-promoted AF and thrombosis are not clear. A possible explanation for this association is that high UA induces oxidative stress and inflammation. Moreover, hyperuricemia was independently associated with increased left atrial diameter (Tamariz et al., 2011; ). Left atrial enlargement is closely related to the occurrence of AF and thrombosis. Furthermore, UA increases Kv1.5 protein expression by activating ERK and oxidative stress in mouse atrial myocytes (HL-1 cells) so as to enhance the ultra-rapid delayed-rectifier K+ channel currents and shorten the action potential duration (Maharani et al., 2015). Additionally, the molecular mechanism of the UA-induced enhancement of Kv1.5 expression also may be attributed to enhanced phosphorylation of Akt and heat shock factor 1 (HSF1), which leads to increased expressions of heat shock protein 70 (Hsp70) (Taufiq et al., 2019).
Although the relationship between hyperuricemia and AF has been widely recognized, the mechanism of occurrence/maintenance of AF caused by hyperuricemia has not been fully elucidated. The available evidence suggests that the UA-induced enhancement of Kv1.5 expression may be a novel mechanism. However, whether intervening can reduce the risk of AF remains unclear. It is clear that prospective intervention studies are needed in the future to demonstrate whether reducing the level of sUA is important for the prevention of AF (Figure 3C).
UA and HF
HF is the end stage of most cardiovascular diseases, which is closely related to hypertension, MI, AF, and valvular heart disease. UA may play an important role in HF. A large number of studies (Vaduganathan et al., 2014; Palazzuoli et al., 2017; Pavlusova et al., 2019) and meta-analyses () have evaluated the relationship between sUA and the risk and adverse outcome of HF. The results indicate that the increase of sUA may be an important risk factor for the incidence and prognosis of HF (; Vaduganathan et al., 2014; Palazzuoli et al., 2017; Pavlusova et al., 2019).
However, the mechanism of hyperuricemia-induced HF and its prognosis is not clear. Inflammation and oxidative stress play key roles in the development and progression of HF. XO is the key enzyme responsible for conversion of purine bases to UA and represents the major source of ROS production in circulation (; ). Therefore, the overactivation of XO may be important for the increase of mortality and hospitalization of patients with high UA and HF. Jia et al. found that the western diet resulted in increased sUA, cardiomyocyte hypertrophy, myocardial oxidative stress, myocardial fibrosis, and diastolic dysfunction (). Further studies found that it may be related to the western diet enhancing the activation of S6 kinase-1 growth pathway and transforming growth factor-β1/Smad2/3 signal pathway and macrophage polarization (). The latest research found that Vericiguat, a stimulator of soluble guanylate cyclase, treatment for 12 weeks, significantly decreases in hs-CRP and sUA in HF patients with reduced ejection fraction (). In addition, our research team also found that high UA stimulates ROS production, inhibits insulin-induced glucose uptake, and thus, leads to myocardial insulin resistance in H9c2 and primary cultured cardiomyocytes (Zhi et al., 2016; Li et al., 2018). Insulin resistance can inhibit the uptake of myocardial glucose, impairing lipid metabolism, leading to myocardial energy metabolism disorder, and thus, affecting the diastolic and contractile function of myocardium. Therefore, high UA-induced myocardial insulin resistance may be an important pathological mechanism of HF. Further study on the molecular mechanism of high UA-induced myocardial insulin resistance may be a novel target for intervention of hyperuricemic-related cardiovascular diseases.
Taken together, the increase of sUA is closely related to the occurrence and prognosis of HF. Inflammation and oxidative stress play key roles in the development and progression of HF. We suggest for the first time that high UA-induced insulin resistance may be an important pathological mechanism of HF. The relationship between high UA-induced myocardial insulin resistance and HF and whether ULT can improve the clinical outcome of patients with HF need to be proved in future studies (Figure 3D).
Urate-lowering Treatments (ULT)
Currently, there are two main classes of ULT drugs commonly used in clinical practice: those inhibiting UA synthesis (XO inhibitors, such as allopurinol, febuxostat, etc.) and increasing UA excretion (e.g., benzbromarone, probenecid, etc.). Current studies confirm that ULT has a good effect in young hypertensive patients, but the effect on CHD, AF, and HF has not achieved satisfactory clinical results. In terms of drug selection, previous studies have suggested that febuxostat is more effective and safer than allopurinol. Recent studies have shown that ULT made no difference in the occurrence of primary end-point events (composite of cardiovascular death, nonfatal MI, nonfatal stroke, or unstable angina with urgent revascularization). However, cardiovascular death appeared to be higher in the febuxostat group compared to the allopurinol group (White et al., 2018). Therefore, febuxostat is neither recommended as the first-line ULT in the latest gout management guidelines nor for the treatment of asymptomatic hyperuricemia. Numerous experimental and clinical studies have confirmed that allopurinol can reduce the incidence of all-cause death, MI, and congestive HF in patients with hyperuricemia (Struthers et al., 2002; MacIsaac et al., 2016; Singh et al., 2017; Nidorf and Jelinek, 2018; Singh and Cleveland, 2018). For drugs promoting the excretion of UA, benzbromarone is superior to probenecid in efficacy and safety. Urate transporter 1 and organic-anion transporter 4 inhibitors, new drugs promoting the excretion of UA, are in the clinical trial stage.
Notably, sodium glucose cotransporter 2 inhibitors (SGLT-2; dapagliflozin, empagliflozin, canagliflozin, etc.) can effectively reduce sUA level by accelerating the excretion of UA (Wilcox et al., 2018; Zhao et al., 2018; Xin et al., 2019). Dapagliflozin, the earliest SGLT-2 inhibitor, reduced the level of UA in a dose-dependent manner. Compared to placebo, dapagliflozin 2.5/5/10 mg can decrease serum UA by 30.9/36.3/47.6 μmol/L, respectively (). The UA-lowering effect of SGLT-2 inhibitors can be attributed to glucose transporter-9 (GLUT-9) isoform 2. SGLT-2 inhibitors increased glucose concentration in renal tubules, activated GLUT-9 in proximal tubules, promoted glucose transport to cells, and excreted UA, and high glucose in collecting tubules inhibited the reabsorption of UA, both of which increased the excretion of UA. Recently, many clinical studies and meta-analyses confirmed that SGLT-2 inhibitors can reduce main cardiovascular adverse events, HF admission rate, and all-cause mortality in patients with hyperuricemia (Zinman et al., 2015; Neal et al., 2017; Wilcox et al., 2018; Zhao et al., 2018; McMurray et al., 2019; Wiviott et al., 2019; Xin et al., 2019). Therefore, SGLT-2 inhibitors are particularly suitable for reducing the risk of cardiovascular death in patients with T2D with hyperuricemia.
Conclusions and Perspectives
Collectively, the relationship between hyperuricemia and cardiovascular disease is becoming clearer, which is attributed to the study progress of UA. First, Tomiyama et al. found that hyperuricemia increased arterial stiffness and inflammation, which may be involved in the risk of development of hypertension. Second, UA induces NLRP3 inflammasome-dependent inflammation activation via the AMPK-mTOR-mROS and HIF-1α pathways. In contrast, decrease of UA level promotes the activation of AMPK and inhibits the formation of atherosclerotic plaque. Furthermore, UA significantly enhances the expression of Kv1.5 protein and enhances Akt and HSF1 phosphorylation, leading to increased Hsp70 expression. This result suggests that inhibition of the Akt-HSF1-Hsp70 pathway may be a novel therapeutic approach against AF in patients with hyperuricemia. Last but not least, high UA induces insulin resistance in cardiomyocytes through the ROS-IRS1/Akt phosphorylation pathway. High UA-induced insulin resistance may be an important pathological mechanism of HF.
A large number of studies have shown that UA levels are positively correlated with hypertension, CHD, AF, and HF (Table 1); however, there was no satisfactory clinical outcome in the ULT of these cardiovascular diseases. Most clinical studies show that febuxostat improves cardiovascular outcomes in patients with gout, but whether it is as effective as allopurinol remains controversial. Allopurinol may increase the risk of serious adverse reactions, so it has not been widely used in clinical practice. Fortunately, SGLT-2 inhibitors (dapagliflozin, etc.) have a good prospect in ULT, meanwhile reducing main cardiovascular adverse events, HF admission rate, and all-cause mortality in patients with T2D and hyperuricemia. However, all of these need to be further confirmed by more large-scale clinical randomized controlled trials.
Table 1
| Study | Study design | Population | No. of Subjects | Main findings/outcomes |
|---|---|---|---|---|
| Hypertension | ||||
| Kuwabura et al., 2018b | Retrospective cohort | Prehypertension | 3584 | Increased sUA is a strong risk marker for developing hypertension from prehypertension |
| Sun et al., 2015 | Prospective randomized | Adolescents | 5478 | A high level of UA indicated a higher likelihood of developing hypertension |
| Meta-analysis (prospective) | Without hypertension | 55607 | Hyperuricemia is associated with an increased risk for incident hypertension, independent of traditional hypertension risk factors | |
| Follow-up RCT | Obese youth with T2D | 539 | Higher baseline sUA independently increased the risk for onset of hypertension | |
| Tomiyama et al., 2018 | Prospective | Men without hypertension | 3274 | Hyperuricemia may have a longitudinal association with the development of hypertension |
| Double-blind placebo RCT | Early Parkinson’s disease patients | 75 | Elevated urate is not association with high BP | |
| RCT | Chronic refractory gout | 212 | ULT can significantly reduce BP | |
| Coronary heart disease | ||||
| Meta-analysis (prospective) | Without CVD | 457915 | Hyperuricemia appears to increase the risk of CHD events in the general population | |
| Retrospective | Under 45 years old diagnosed with EOCAD | 786 | sUA >8 mg/dl was independently associated with triple branches involvement, HF and LV enlargement | |
| von Lueder et al., 2015 | Meta-analysis | Four clinical trials | 12677 | Elevated sUA is associated with poor outcomes |
| Li M. et al., 2016 | Systematic review (prospective) | Hyperuricemia or elevated sUA level | 958410 | Hyperuricemia was associated with increased risk of CHD morbidity and mortality |
| Wang R. et al., 2016 | Meta-analysis | With suspected or definite CHD | 25229 | Elevated sUA levels are strongly and independently associated with greater risk of cardiovascular and all-cause mortality |
| Retrospective cohort | CT evaluation of CAC | 9297 | sUA was an independent predictor for development of moderate CAC in subjects with no or minimal calcification | |
| Atrial fibrillation | ||||
| Retrospective | Without general cardiovascular risk | 49292 | Hyperuricemia is an independent competing risk factor for AF | |
| Zhang et al., 2016 | Meta-analysis (prospective) | Hyperuricemia | 426159 | Hyperuricemia is associated with increased risk of AF |
| Pak et al., 2018 | Meta-analysis | With and without AF | 30609 | The mean SUA level of patients with AF significantly is higher than those without AF |
| Prospective | Paroxysmal AF undergoing cryoablation | 363 | sUA levels were associated with a higher rate of AF recurrence | |
| Zhao et al., 2016 | Meta-analysis | AF undergoing cryoablation | 1298 | Elevated sUA is not associated with increased risk of AF recurrence after catheter ablation |
| Heart failure | ||||
| Pavlusova et al., 2019 | Prospective | Acute HF | 3610 | Hyperuricemia was associated with an unfavorable cardiovascular risk |
| Palazzuoli et al., 2017 | Prospective | Acute HF | 324 | Hyperuricemia was the only independent predictor of HF hospitalization or death |
| Vaduganathan et al., 2014 | Double-blind placebo RCT | Worsening chronic HF | 3955 | sUA is commonly elevated in patients hospitalized for worsening chronic HF |
| Meta-analysis | Chronic HF | 427917 | Elevated sUA is associated with an increased risk of incident HF and adverse outcomes in HF patients | |
Pivotal clinical studies on the relationship between sUA level and cardiovascular disease.
Numerous clinical studies and meta-analysis have shown that UA levels are significantly positively correlated with cardiovascular diseases, including hypertension, coronary atherosclerosis, AF, and HF.
AF, atrial fibrillation; BP, blood pressure; CAC, coronary artery calcium; CHD, coronary heart disease; CT, computed tomography; CVD, cardiovascular disease; EOCAD, early-onset coronary artery disease; HF, heart failure; LV, left ventricle; RCT, randomized controlled trial; sUA, serum uric acid; T2D, type 2 diabetes; UA, uric acid; ULT, uric acid-lowering treatments.
Funding
This work was supported by grants from the National Natural Science Foundation of China (81570772 and 81471081), the Natural Science Foundation of Fujian Province (2020J01010) and the Xiang’an Hospital of Xiamen University (PM201809170002).
Statements
Author contributions
WY initiated this review, read lots of literature, and wrote the manuscript. J-DC revised our first draft and provided valuable comments. All authors contributed to the article and approved the submitted version.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1
AlbertsB. M.BarberJ. S.SacreS. M.DaviesK. A.GhezziP.MullenL. M. (2019). Precipitation of Soluble Uric Acid Is Necessary for In Vitro Activation of the NLRP3 Inflammasome in Primary Human Monocytes. J. Rheumatol.46 (9), 1141–1150. doi: 10.3899/jrheum.180855
2
AmesB. N.CathcartR.SchwiersE.HochsteinP. (1981). Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc. Natl. Acad. Sci. U.S.A.78 (11), 6858–6862. doi: 10.1073/pnas.78.11.6858
3
AroorA. R.DemarcoV. G.JiaG.SunZ.NistalaR.MeiningerG. A.et al. (2013). The role of tissue Renin-Angiotensin-aldosterone system in the development of endothelial dysfunction and arterial stiffness. Front. Endocrinol. (Lausanne)4, 161. doi: 10.3389/fendo.2013.00161
4
BaileyC. J.GrossJ. L.PietersA.BastienA.ListJ. F. (2010). Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet375 (9733), 2223–2233. doi: 10.1016/S0140-6736(10)60407-2
5
BattelliM. G.BortolottiM.PolitoL.BolognesiA. (2018). The role of xanthine oxidoreductase and uric acid in metabolic syndrome. Biochim. Biophys. Acta Mol. Basis Dis.1864 (8), 2557–2565. doi: 10.1016/j.bbadis.2018.05.003
6
BeneN. C.AlcaideP.WortisH. H.JaffeI. Z. (2014). Mineralocorticoid receptors in immune cells: emerging role in cardiovascular disease. Steroids91, 38–45. doi: 10.1016/j.steroids.2014.04.005
7
BjornstadP.LaffelL.LynchJ.El GhormliL.WeinstockR. S.TollefsenS. E.et al. (2019). Elevated Serum Uric Acid Is Associated With Greater Risk for Hypertension and Diabetic Kidney Diseases in Obese Adolescents With Type 2 Diabetes: An Observational Analysis From the Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) Study. Diabetes Care42 (6), 1120–1128. doi: 10.2337/dc18-2147
8
Black-MaierE.DaubertJ. P. (2019). Editorial Commentary: Prevention and treatment of atrial fibrillation: Is hyperuricemia the next target? Trends Cardiovasc. Med.29 (1), 48–49. doi: 10.1016/j.tcm.2018.07.006
9
BobanM.KocicG.RadenkovicS.PavlovicR.CvetkovicT.Deljanin-IlicM.et al. (2014). Circulating purine compounds, uric acid, and xanthine oxidase/dehydrogenase relationship in essential hypertension and end stage renal disease. Ren. Fail36 (4), 613–618. doi: 10.3109/0886022X.2014.882240
10
BorgiL.McMullanC.WohlhueterA.CurhanG. C.FisherN. D.FormanJ. P. (2017). Effect of Uric Acid-Lowering Agents on Endothelial Function: A Randomized, Double-Blind, Placebo-Controlled Trial. Hypertension69 (2), 243–248. doi: 10.1161/HYPERTENSIONAHA.116.08488
11
BragaF.PasqualettiS.FerraroS.PanteghiniM. (2016). Hyperuricemia as risk factor for coronary heart disease incidence and mortality in the general population: a systematic review and meta-analysis. Clin. Chem. Lab. Med.54 (1), 7–15. doi: 10.1515/cclm-2015-0523
12
CaiW.DuanX. M.LiuY.YuJ.TangY. L.LiuZ. L.et al. (2017). Uric Acid Induces Endothelial Dysfunction by Activating the HMGB1/RAGE Signaling Pathway. BioMed. Res. Int.2017:4391920. doi: 10.1155/2017/4391920
13
CanpolatU.AytemirK.YorgunH.SahinerL.KayaE. B.CayS.et al. (2014). Usefulness of serum uric acid level to predict atrial fibrillation recurrence after cryoballoon-based catheter ablation. Europace16 (12), 1731–1737. doi: 10.1093/europace/euu198
14
CelikM.YalcinkayaE.YukselU. C.GokoglanY.BuganB.KabulH. K.et al. (2015). Increased serum uric acid levels are correlated with decreased left atrial appendage peak flow velocity in patients with atrial fibrillation. Med. Princ. Pract.24 (3), 263–268. doi: 10.1159/000373892
15
ChenY.XiaY.HanX.YangY.YinX.QiuJ.et al. (2017). Association between serum uric acid and atrial fibrillation: a cross-sectional community-based study in China. BMJ Open7 (12), e019037. doi: 10.1136/bmjopen-2017-019037
16
ChenX.UmehC. C.TainshR. E.FengD. D.MaguireM.ZuoF.et al. (2018). Dissociation between urate and blood pressure in mice and in people with early Parkinson’s disease. EBioMedicine37, 259–268. doi: 10.1016/j.ebiom.2018.10.039
17
ChenC. H.ChenC. B.ChangC. J.LinY. J.WangC. W.ChiC. C.et al. (2019). Hypersensitivity and Cardiovascular Risks Related to Allopurinol and Febuxostat Therapy in Asians: A Population-Based Cohort Study and Meta-Analysis. Clin. Pharmacol. Ther.106 (2), 391–401. doi: 10.1002/cpt.1377
18
CiceroA. F.SalviP.D’AddatoS.RosticciM.BorghiC.Brisighella Heart Study, g (2014). Association between serum uric acid, hypertension, vascular stiffness and subclinical atherosclerosis: data from the Brisighella Heart Study. J. Hypertens.32 (1), 57–64. doi: 10.1097/HJH.0b013e328365b916
19
CorryD. B.EslamiP.YamamotoK.NybyM. D.MakinoH.TuckM. L. (2008). Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system. J. Hypertens.26 (2), 269–275. doi: 10.1097/HJH.0b013e3282f240bf
20
CulletonB. F.LarsonM. G.KannelW. B.LevyD. (1999). Serum Uric Acid and Risk for Cardiovascular Disease and Death: The Framingham Heart Study. Ann. Intern. Med.131 (1), 7–13. doi: 10.7326/0003-4819-131-1-199907060-00003
21
DaiX. M.WeiL.MaL. L.ChenH. Y.ZhangZ. J.JiZ. F.et al. (2015). Serum uric acid and its relationship with cardiovascular risk profile in Chinese patients with early-onset coronary artery disease. Clin. Rheumatol.34 (9), 1605–1611. doi: 10.1007/s10067-015-2878-1
22
DaviesK. J.SevanianA.Muakkassah-KellyS. F.HochsteinP. (1986). Uric acid-iron ion complexes. A new aspect of the antioxidant functions of uric acid. Biochem. J.235 (3), 747–754. doi: 10.1042/bj2350747
23
DoehnerW.SchoeneN.RauchhausM.Leyva-LeonF.PavittD. V.ReaveleyD. A.et al. (2002). Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies. Circulation105 (22), 2619–2624. doi: 10.1161/01.cir.0000017502.58595.ed
24
FarquharsonC. A.ButlerR.HillA.BelchJ. J.StruthersA. D. (2002). Allopurinol improves endothelial dysfunction in chronic heart failure. Circulation106 (2), 221–226. doi: 10.1161/01.cir.0000022140.61460.1d
25
FormanJ. P.ChoiH.CurhanG. C. (2009). Uric acid and insulin sensitivity and risk of incident hypertension. Arch. Intern. Med.169 (2), 155–162. doi: 10.1001/archinternmed.2008.521
26
GeorgeJ.CarrE.DaviesJ.BelchJ. J.StruthersA. (2006). High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation114 (23), 2508–2516. doi: 10.1161/CIRCULATIONAHA.106.651117
27
GerschC.PaliiS. P.ImaramW.KimK. M.KarumanchiS. A.AngerhoferA.et al. (2009). Reactions of peroxynitrite with uric acid: formation of reactive intermediates, alkylated products and triuret, and in vivo production of triuret under conditions of oxidative stress. Nucleosides Nucleotides Nucleic Acids28 (2), 118–149. doi: 10.1080/15257770902736400
28
GraysonP. C.KimS. Y.LaValleyM.ChoiH. K. (2011). Hyperuricemia and incident hypertension: a systematic review and meta-analysis. Arthritis Care Res. (Hoboken)63 (1), 102–110. doi: 10.1002/acr.20344
29
HaoY.LiH.CaoY.ChenY.LeiM.ZhangT.et al. (2019). Uricase and Horseradish Peroxidase Hybrid CaHPO(4) Nanoflower Integrated with Transcutaneous Patches for Treatment of Hyperuricemia. J. BioMed. Nanotechnol.15 (5), 951–965. doi: 10.1166/jbn.2019.2752
30
HoW. J.TsaiW. P.YuK. H.TsayP. K.WangC. L.HsuT. S.et al. (2010). Association between endothelial dysfunction and hyperuricaemia. Rheumatol. (Oxford)49 (10), 1929–1934. doi: 10.1093/rheumatology/keq184
31
HuangH.HuangB.LiY.HuangY.LiJ.YaoH.et al. (2014). Uric acid and risk of heart failure: a systematic review and meta-analysis. Eur. J. Heart Fail16 (1), 15–24. doi: 10.1093/eurjhf/hft132
32
HuangT. T.HaoD. L.WuB. N.MaoL. L.ZhangJ. (2017). Uric acid demonstrates neuroprotective effect on Parkinson’s disease mice through Nrf2-ARE signaling pathway. Biochem. Biophys. Res. Commun.493 (4), 1443–1449. doi: 10.1016/j.bbrc.2017.10.004
33
InabaS.SautinY.GarciaG. E.JohnsonR. J. (2013). What can asymptomatic hyperuricaemia and systemic inflammation in the absence of gout tell us? Rheumatol. (Oxford)52 (6), 963–965. doi: 10.1093/rheumatology/ket001
34
JiaG.HabibiJ.BostickB. P.MaL.DeMarcoV. G.AroorA. R.et al. (2015). Uric acid promotes left ventricular diastolic dysfunction in mice fed a Western diet. Hypertension65 (3), 531–539. doi: 10.1161/HYPERTENSIONAHA.114.04737
35
JohnsonR. J.BakrisG. L.BorghiC.ChoncholM. B.FeldmanD.LanaspaM. A.et al. (2018). Hyperuricemia, Acute and Chronic Kidney Disease, Hypertension, and Cardiovascular Disease: Report of a Scientific Workshop Organized by the National Kidney Foundation. Am. J. Kidney Dis.71 (6), 851–865. doi: 10.1053/j.ajkd.2017.12.009
36
JohnsonR. J.ChoiH. K.YeoA. E.LipskyP. E. (2019). Pegloticase Treatment Significantly Decreases Blood Pressure in Patients With Chronic Gout. Hypertension74 (1), 95–101. doi: 10.1161/HYPERTENSIONAHA.119.12727
37
JunJ. E.LeeY. B.LeeS. E.AhnJ. Y.KimG.JinS. M.et al. (2018). Elevated serum uric acid predicts the development of moderate coronary artery calcification independent of conventional cardiovascular risk factors. Atherosclerosis272, 233–239. doi: 10.1016/j.atherosclerosis.2018.02.014
38
KatoM.HisatomeI.TomikuraY.KotaniK.KinugawaT.OginoK.et al. (2005). Status of endothelial dependent vasodilation in patients with hyperuricemia. Am. J. Cardiol.96 (11), 1576–1578. doi: 10.1016/j.amjcard.2005.07.068
39
KatsikiN.MikhailidisD. P. (2015). Hyperuricaemia in cardiovascular diseases: a passive or an active player? Med. Princ. Pract.24 (3), 269–270. doi: 10.1159/000381398
40
KhaliqO. P.KonoshitaT.MoodleyJ.NaickerT. (2018). The Role of Uric Acid in Preeclampsia: Is Uric Acid a Causative Factor or a Sign of Preeclampsia? Curr. Hypertens. Rep.20 (9), 80. doi: 10.1007/s11906-018-0878-7
41
KimS. K.ChoeJ. Y.ParkK. Y. (2019). Anti-inflammatory effect of artemisinin on uric acid-induced NLRP3 inflammasome activation through blocking interaction between NLRP3 and NEK7. Biochem. Biophys. Res. Commun.517 (2), 338–345. doi: 10.1016/j.bbrc.2019.07.087
42
KimuraY.YanagidaT.OndaA.TsukuiD.HosoyamadaM.KonoH. (2020). Soluble Uric Acid Promotes Atherosclerosis via AMPK (AMP-Activated Protein Kinase)-Mediated Inflammation. Arterioscler. Thromb. Vasc. Biol.40 (3), 570–582. doi: 10.1161/ATVBAHA.119.313224
43
KlisicA.KocicG.KavaricN.JovanovicM.StanisicV.NinicA. (2018). Xanthine oxidase and uric acid as independent predictors of albuminuria in patients with diabetes mellitus type 2. Clin. Exp. Med.18 (2), 283–290. doi: 10.1007/s10238-017-0483-0
44
KobayashiN.AsaiK.TsurumiM.ShibataY.OkazakiH.ShirakabeA.et al. (2018). Impact of Accumulated Serum Uric Acid on Coronary Culprit Lesion Morphology Determined by Optical Coherence Tomography and Cardiac Outcomes in Patients with Acute Coronary Syndrome. Cardiology141 (4), 190–198. doi: 10.1159/000496053
45
KodamaS.SaitoK.YachiY.AsumiM.SugawaraA.TotsukaK.et al. (2009). Association between serum uric acid and development of type 2 diabetes. Diabetes Care32 (9), 1737–1742. doi: 10.2337/dc09-0288
46
KramerF.VossS.RoessigL.IglB. W.ButlerJ.LamC. S. P.et al. (2020). Evaluation of high-sensitivity C-reactive protein and uric acid in vericiguat-treated patients with heart failure with reduced ejection fraction. Eur. J. Heart Fail.22 (9), 1675–1683. doi: 10.1002/ejhf.1787
47
KushiyamaA.NakatsuY.MatsunagaY.YamamotoyaT.MoriK.UedaK.et al. (2016). Role of Uric Acid Metabolism-Related Inflammation in the Pathogenesis of Metabolic Syndrome Components Such as Atherosclerosis and Nonalcoholic Steatohepatitis. Mediators Inflammation2016, 1–15. doi: 10.1155/2016/8603164
48
KuwabaraM.KuwabaraR.HisatomeI.NiwaK.Roncal-JimenezC. A.BjornstadP.et al. (2017a). “Metabolically Healthy” Obesity and Hyperuricemia Increase Risk for Hypertension and Diabetes: 5-year Japanese Cohort Study. Obes. (Silver Spring)25 (11), 1997–2008. doi: 10.1002/oby.22000
49
KuwabaraM.NiwaK.HisatomeI.NakagawaT.Roncal-JimenezC. A.Andres-HernandoA.et al. (2017b). Asymptomatic Hyperuricemia Without Comorbidities Predicts Cardiometabolic Diseases: Five-Year Japanese Cohort Study. Hypertension69 (6), 1036–1044. doi: 10.1161/HYPERTENSIONAHA.116.08998
50
KuwabaraM.NiwaK.NishiharaS.NishiY.TakahashiO.KarioK.et al. (2017c). Hyperuricemia is an independent competing risk factor for atrial fibrillation. Int. J. Cardiol.231, 137–142. doi: 10.1016/j.ijcard.2016.11.268
51
KuwabaraM.BorghiC.CiceroA. F. G.HisatomeI.NiwaK.OhnoM.et al. (2018a). Elevated serum uric acid increases risks for developing high LDL cholesterol and hypertriglyceridemia: A five-year cohort study in Japan. Int. J. Cardiol.261, 183–188. doi: 10.1016/j.ijcard.2018.03.045
52
KuwabaraM.HisatomeI.NiwaK.HaraS.Roncal-JimenezC. A.BjornstadP.et al. (2018b). Uric Acid Is a Strong Risk Marker for Developing Hypertension From Prehypertension: A 5-Year Japanese Cohort Study. Hypertension71 (1), 78–86. doi: 10.1161/HYPERTENSIONAHA.117.10370
53
LiZ.ShenY.ChenY.ZhangG.ChengJ.WangW. (2018). High Uric Acid Inhibits Cardiomyocyte Viability Through the ERK/P38 Pathway via Oxidative Stress. Cell Physiol. Biochem.45 (3), 1156–1164. doi: 10.1159/000487356
54
LiH.QianF.LiuH.ZhangZ. (2019). Elevated Uric Acid Levels Promote Vascular Smooth Muscle Cells (VSMC) Proliferation via an Nod-Like Receptor Protein 3 (NLRP3)-Inflammasome-Dependent Mechanism. Med. Sci. Monit.25, 8457–8464. doi: 10.12659/MSM.916667
55
LiM.HuX.FanY.LiK.ZhangX.HouW.et al. (2016). Hyperuricemia and the risk for coronary heart disease morbidity and mortality a systematic review and dose-response meta-analysis. Sci. Rep.6, 19520. doi: 10.1038/srep19520
56
LiP.ZhangL.ZhangM.ZhouC.LinN. (2016). Uric acid enhances PKC-dependent eNOS phosphorylation and mediates cellular ER stress: A mechanism for uric acid-induced endothelial dysfunction. Int. J. Mol. Med.37 (4), 989–997. doi: 10.3892/ijmm.2016.2491
57
LiangW. Y.LiuW. W.LiuM. L.XiangW.FengX. R.HuangB.et al. (2016). Serum uric acid level and left ventricular hypertrophy in elderly male patients with nonvalvular atrial fibrillation. Nutr. Metab. Cardiovasc. Dis.26 (7), 575–580. doi: 10.1016/j.numecd.2016.03.011
58
LinW. D.DengH.GuoP.LiuF. Z.ChenR. Y.FangX. H.et al. (2019). High prevalence of hyperuricaemia and its impact on non-valvular atrial fibrillation: the cross-sectional Guangzhou (China) Heart Study. BMJ Open9 (5), e028007. doi: 10.1136/bmjopen-2018-028007
59
LiuP.WangH.ZhangF.ChenY.WangD.WangY. (2015). The Effects of Allopurinol on the Carotid Intima-media Thickness in Patients with Type 2 Diabetes and Asymptomatic Hyperuricemia: A Three-year Randomized Parallel-controlled Study. Intern. Med.54 (17), 2129–2137. doi: 10.2169/internalmedicine.54.4310
60
LuJ.SunM.WuX.YuanX.LiuZ.QuX.et al. (2019). Urate-lowering therapy alleviates atherosclerosis inflammatory response factors and neointimal lesions in a mouse model of induced carotid atherosclerosis. FEBS J.286 (7), 1346–1359. doi: 10.1111/febs.14768
61
LuJ.HeY.CuiL.XingX.LiuZ.LiX.et al. (2020). Hyperuricemia Predisposes to the Onset of Diabetes via Promoting Pancreatic beta-Cell Death in Uricase-Deficient Male Mice. Diabetes69 (6), 1149–1163. doi: 10.2337/db19-0704
62
MacIsaacR. L.SalatzkiJ.HigginsP.WaltersM. R.PadmanabhanS.DominiczakA. F.et al. (2016). Allopurinol and Cardiovascular Outcomes in Adults With Hypertension. Hypertension67 (3), 535–540. doi: 10.1161/HYPERTENSIONAHA.115.06344
63
MaharaniN.TingY. K.ChengJ.HasegawaA.KurataY.LiP.et al. (2015). Molecular Mechanisms Underlying Urate-Induced Enhancement of Kv1.5 Channel Expression in HL-1 Atrial Myocytes. Circ. J.79 (12), 2659–2668. doi: 10.1253/circj.CJ-15-0416
64
MantovaniA.RigolonR.CivettiniA.BolzanB.MoraniG.BonapaceS.et al. (2018). Hyperuricemia is associated with an increased prevalence of paroxysmal atrial fibrillation in patients with type 2 diabetes referred for clinically indicated 24-h Holter monitoring. J. Endocrinol. Invest.41 (2), 223–231. doi: 10.1007/s40618-017-0729-4
65
MartinonF.PetrilliV.MayorA.TardivelA.TschoppJ. (2006). Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature440 (7081), 237–241. doi: 10.1038/nature04516
66
MaruhashiT.NakashimaA.SogaJ.FujimuraN.IdeiN.MikamiS.et al. (2013). Hyperuricemia is independently associated with endothelial dysfunction in postmenopausal women but not in premenopausal women. BMJ Open3 (11), e003659. doi: 10.1136/bmjopen-2013-003659
67
MaruhashiT.HisatomeI.KiharaY.HigashiY. (2018). Hyperuricemia and endothelial function: From molecular background to clinical perspectives. Atherosclerosis278, 226–231. doi: 10.1016/j.atherosclerosis.2018.10.007
68
MatiasM. L.RomaoM.WeelI. C.RibeiroV. R.NunesP. R.BorgesV. T.et al. (2015). Endogenous and Uric Acid-Induced Activation of NLRP3 Inflammasome in Pregnant Women with Preeclampsia. PloS One10 (6), e0129095. doi: 10.1371/journal.pone.0129095
69
McMurrayJ. J. V.SolomonS. D.InzucchiS. E.KoberL.KosiborodM. N.MartinezF. A.et al. (2019). Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl. J. Med.381 (21), 1995–2008. doi: 10.1056/NEJMoa1911303
70
MercuroG.VitaleC.CerquetaniE.ZoncuS.DeiddaM.FiniM.et al. (2004). Effect of hyperuricemia upon endothelial function in patients at increased cardiovascular risk. Am. J. Cardiol.94 (7), 932–935. doi: 10.1016/j.amjcard.2004.06.032
71
MortadaI. (2017). Hyperuricemia, Type 2 Diabetes Mellitus, and Hypertension: an Emerging Association. Curr. Hypertens. Rep.19 (9), 69. doi: 10.1007/s11906-017-0770-x
72
NealB.PerkovicV.MahaffeyK. W.de ZeeuwD.FulcherG.EronduN.et al. (2017). Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl. J. Med.377 (7), 644–657. doi: 10.1056/NEJMoa1611925
73
NidorfM.JelinekM. (2018). Serendipity: How the search for meaning of serum uric acid might lead to the repurposing of an old drug in patients with cardiovascular disease. Eur. J. Prev. Cardiol.25 (3), 231–232. doi: 10.1177/2047487317749039
74
NomanA.AngD. S. C.OgstonS.LangC. C.StruthersA. D. (2010). Effect of High-Dose Allopurinol on Exercise in Patients With Chronic Stable Angina: A Randomised, Placebo Controlled Crossover Trial. Lancet375 (9732), 2161–2167. doi: 10.1016/S0140-6736(10)60391-1
75
OzturkD.CelikO.AkinF.AkturkF.AslanS.OzyilmazS. O.et al. (2015). Usefulness of the uric acid and CHA(2)DS(2)-VASc score in prediction of left atrial thrombosis in patients with mitral stenosis and sinus rhythm. Cardiol. J.22 (3), 336–342. doi: 10.5603/CJ.a2014.0059
76
PakS.YatsynovichY.ValenciaD.ChenT. (2018). Serum Uric Acid and Atrial Fibrillation: Meta-analysis. Crit. Pathw. Cardiol.17 (3), 161–166. doi: 10.1097/HPC.0000000000000150
77
PalazzuoliA.RuoccoG.De VivoO.NutiR.McCulloughP. A. (2017). Prevalence of Hyperuricemia in Patients With Acute Heart Failure With Either Reduced or Preserved Ejection Fraction. Am. J. Cardiol.120 (7), 1146–1150. doi: 10.1016/j.amjcard.2017.06.057
78
PapezikovaI.PekarovaM.KolarovaH.KlinkeA.LauD.BaldusS.et al. (2013). Uric acid modulates vascular endothelial function through the down regulation of nitric oxide production. Free Radic. Res.47 (2), 82–88. doi: 10.3109/10715762.2012.747677
79
PavlusovaM.JarkovskyJ.BenesovaK.VitovecJ.LinhartA.WidimskyP.et al. (2019). Hyperuricemia treatment in acute heart failure patients does not improve their long-term prognosis: A propensity score matched analysis from the AHEAD registry. Clin. Cardiol.42 (8), 720–727. doi: 10.1002/clc.23197
80
PrasadM.MattesonE. L.HerrmannJ.GulatiR.RihalC. S.LermanL. O.et al. (2017). Uric Acid Is Associated With Inflammation, Coronary Microvascular Dysfunction, and Adverse Outcomes in Postmenopausal Women. Hypertension69 (2), 236–242. doi: 10.1161/HYPERTENSIONAHA.116.08436
81
RekhrajS.GandyS. J.SzwejkowskiB. R.NadirM. A.NomanA.HoustonJ. G.et al. (2013). High-dose allopurinol reduces left ventricular mass in patients with ischemic heart disease. J. Am. Coll. Cardiol.61 (9), 926–932. doi: 10.1016/j.jacc.2012.09.066
82
RitchieR. H. (2009). Evidence for a causal role of oxidative stress in the myocardial complications of insulin resistance. Heart Lung Circ.18 (1), 11–18. doi: 10.1016/j.hlc.2008.11.003
83
SakrH. I.KhowailedA. A.Al-FakharanyR. S.Abdel-FattahD. S.TahaA. A. (2020). Serum Uric Acid Level as a Predictive Biomarker of Gestational Hypertension Severity; A Prospective Observational Case-Control Study. Rev. Recent Clin. Trials15 (3), 227–239. doi: 10.2174/1574887115666200709142119
84
SautinY. Y.JohnsonR. J. (2008). Uric acid: the oxidant-antioxidant paradox. Nucleosides Nucleotides Nucleic Acids27 (6), 608–619. doi: 10.1080/15257770802138558
85
SincerI.KurtogluE.CaliskanM.AkkayaE.VuruskanE.KucukosmanogluM.et al. (2014). Significant correlation between uric acid levels and flow-mediated dilatation in patients with masked hypertension. Clin. Exp. Hypertens.36 (5), 315–320. doi: 10.3109/10641963.2013.827694
86
SinghJ. A.ClevelandJ. (2018). Allopurinol and the risk of incident peripheral arterial disease in the elderly: a US Medicare claims data study. Rheumatol. (Oxford)57 (3), 451–461. doi: 10.1093/rheumatology/kex232
87
SinghJ. A.RamachandaranR.YuS.CurtisJ. R. (2017). Allopurinol use and the risk of acute cardiovascular events in patients with gout and diabetes. BMC Cardiovasc. Disord.17 (1), 76. doi: 10.1186/s12872-017-0513-6
88
SinghG.LingalaB.MithalA. (2019). Gout and hyperuricaemia in the USA: prevalence and trends. Rheumatol. (Oxford)58 (12), 2177–2180. doi: 10.1093/rheumatology/kez196
89
StruthersA. D.DonnanP. T.LindsayP.McNaughtonD.BroomhallJ.MacDonaldT. M. (2002). Effect of allopurinol on mortality and hospitalisations in chronic heart failure: a retrospective cohort study. Heart87 (3), 229–234. doi: 10.1136/heart.87.3.229
90
SunH. L.PeiD.LueK. H.ChenY. L. (2015). Uric Acid Levels Can Predict Metabolic Syndrome and Hypertension in Adolescents: A 10-Year Longitudinal Study. PloS One10 (11), e0143786. doi: 10.1371/journal.pone.0143786
91
SunX.JiaoH.ZhaoJ.WangX.LinH. (2017). Unexpected effect of urate on hydrogen peroxide-induced oxidative damage in embryonic chicken cardiac cells. Free Radic. Res.51 (7-8), 693–707. doi: 10.1080/10715762.2017.1362106
92
SzwejkowskiB. R.GandyS. J.RekhrajS.HoustonJ. G.LangC. C.MorrisA. D.et al. (2013). Allopurinol reduces left ventricular mass in patients with type 2 diabetes and left ventricular hypertrophy. J. Am. Coll. Cardiol.62 (24), 2284–2293. doi: 10.1016/j.jacc.2013.07.074
93
TamarizL.AgarwalS.SolimanE. Z.ChamberlainA. M.PrineasR.FolsomA. R.et al. (2011). Association of serum uric acid with incident atrial fibrillation (from the Atherosclerosis Risk in Communities [ARIC] study). Am. J. Cardiol.108 (9), 1272–1276. doi: 10.1016/j.amjcard.2011.06.043
94
TangR. B.DongJ. Z.YanX. L.DuX.KangJ. P.WuJ. H.et al. (2014). Serum uric acid and risk of left atrial thrombus in patients with nonvalvular atrial fibrillation. Can. J. Cardiol.30 (11), 1415–1421. doi: 10.1016/j.cjca.2014.06.009
95
TaufiqF.MaharaniN.LiP.KurataY.IkedaN.KuwabaraM.et al. (2019). Uric Acid-Induced Enhancements of Kv1.5 Protein Expression and Channel Activity via the Akt-HSF1-Hsp70 Pathway in HL-1 Atrial Myocytes. Circ. J.83 (4), 718–726. doi: 10.1253/circj.CJ-18-1088
96
TomiyamaH.HigashiY.TakaseB.NodeK.SataM.InoueT.et al. (2011). Relationships among hyperuricemia, metabolic syndrome, and endothelial function. Am. J. Hypertens.24 (7), 770–774. doi: 10.1038/ajh.2011.55
97
TomiyamaH.ShiinaK.VlachopoulosC.IwasakiY.MatsumotoC.KimuraK.et al. (2018). Involvement of Arterial Stiffness and Inflammation in Hyperuricemia-Related Development of Hypertension. Hypertension72 (3), 739–745. doi: 10.1161/HYPERTENSIONAHA.118.11390
98
VaduganathanM.GreeneS. J.AmbrosyA. P.MentzR. J.SubaciusH. P.ChioncelO.et al. (2014). Relation of serum uric acid levels and outcomes among patients hospitalized for worsening heart failure with reduced ejection fraction (from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan trial). Am. J. Cardiol.114 (11), 1713–1721. doi: 10.1016/j.amjcard.2014.09.008
99
van der SchaftN.BrahimajA.WenK. X.FrancoO. H.DehghanA. (2017). The association between serum uric acid and the incidence of prediabetes and type 2 diabetes mellitus: The Rotterdam Study. PloS One12 (6), e0179482. doi: 10.1371/journal.pone.0179482
100
VaneJ. R.AnggardE. E.BottingR. M. (1990). Regulatory functions of the vascular endothelium. N Engl. J. Med.323, 27–36. doi: 10.1056/NEJM199007053230106
101
VirdisA.MasiS.CasigliaE.TikhonoffV.CiceroA. F. G.UngarA.et al. (2020). Identification of the Uric Acid Thresholds Predicting an Increased Total and Cardiovascular Mortality Over 20 Years. Hypertension75 (2), 302–308. doi: 10.1161/hypertensionaha.119.13643
102
von LuederT. G.GirerdN.AtarD.AgewallS.LamiralZ.KanbayM.et al. (2015). Serum uric acid is associated with mortality and heart failure hospitalizations in patients with complicated myocardial infarction: findings from the High-Risk Myocardial Infarction Database Initiative. Eur. J. Heart Fail17 (11), 1144–1151. doi: 10.1002/ejhf.419
103
WangG. L.YuanH. M.WangZ. F.ZongB. B.YeY.ZhangJ.et al. (2018). Soluble Uric Acid Activates NLRP3 Inflammasome in Myocardial Cells Through Down-regulating UCP2. Sichuan Da Xue Xue Bao Yi Xue Ban (Article Chinese)49 (4), 512–517.
104
WangI. K.ChenJ. H.MuoC. H.ChouC. Y.LiuY. L.LinS. Y.et al. (2016). Subsequent risk of gout for women with hypertensive disorders in pregnancy: a retrospective cohort study. J. Hypertens.34 (5), 914–919. doi: 10.1097/HJH.0000000000000888
105
WangR.SongY.YanY.DingZ. (2016). Elevated serum uric acid and risk of cardiovascular or all-cause mortality in people with suspected or definite coronary artery disease: A meta-analysis. Atherosclerosis254, 193–199. doi: 10.1016/j.atherosclerosis.2016.10.006
106
WaringW. S.WebbD. J.MaxwellS. R. (2001). Systemic uric acid administration increases serum antioxidant capacity in healthy volunteers. J. Cardiovasc. Pharmacol.38 (3), 365–371. doi: 10.1097/00005344-200109000-00005
107
WhiteW. B.SaagK. G.BeckerM. A.BorerJ. S.GorelickP. B.WheltonA.et al. (2018). Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout. N Engl. J. Med.378 (13), 1200–1210. doi: 10.1056/NEJMoa1710895
108
WhitemanM.KetsawatsakulU.HalliwellB. (2002). A reassessment of the peroxynitrite scavenging activity of uric acid. Ann. N Y Acad. Sci.962, 242–259. doi: 10.1111/j.1749-6632.2002.tb04072.x
109
WilcoxC. S.ShenW.BoultonD. W.LeslieB. R.GriffenS. C. (2018). Interaction Between the Sodium-Glucose-Linked Transporter 2 Inhibitor Dapagliflozin and the Loop Diuretic Bumetanide in Normal Human Subjects. J. Am. Heart Assoc.7 (4), e007046. doi: 10.1161/JAHA.117.007046
110
WiviottS. D.RazI.BonacaM. P.MosenzonO.KatoE. T.CahnA.et al. (2019). Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl. J. Med.380 (4), 347–357. doi: 10.1056/NEJMoa1812389
111
WuG. J.HanY. L.WangX. Z. (2012). Research Progress on the relationship between hyperuricemia and coronary heart disease. Chin. J. Cardiovasc. Rehablil. Med.21 (2), 216–217.
112
XiaoJ.ZhangX. L.FuC.HanR.ChenW.LuY.et al. (2015). Soluble uric acid increases NALP3 inflammasome and interleukin-1beta expression in human primary renal proximal tubule epithelial cells through the Toll-like receptor 4-mediated pathway. Int. J. Mol. Med.35 (5), 1347–1354. doi: 10.3892/ijmm.2015.2148
113
XinY.GuoY.LiY.MaY.LiL.JiangH. (2019). Effects of sodium glucose cotransporter-2 inhibitors on serum uric acid in type 2 diabetes mellitus: A systematic review with an indirect comparison meta-analysis. Saudi J. Biol. Sci.26 (2), 421–426. doi: 10.1016/j.sjbs.2018.11.013
114
YanM.ChenK.HeL.LiS.HuangD.LiJ. (2018). Uric Acid Induces Cardiomyocyte Apoptosis via Activation of Calpain-1 and Endoplasmic Reticulum Stress. Cell Physiol. Biochem.45 (5), 2122–2135. doi: 10.1159/000488048
115
YinW.ZhouQ. L.OuYangS. X.ChenY.GongY. T.LiangY. M. (2019). Uric acid regulates NLRP3/IL-1beta signaling pathway and further induces vascular endothelial cells injury in early CKD through ROS activation and K(+) efflux. BMC Nephrol.20 (1), 319. doi: 10.1186/s12882-019-1506-8
116
YuM.-A.Sánchez-LozadaL. G.JohnsonR. J.KangD.-H. (2010). Oxidative stress with an activation of the renin–angiotensin system in human vascular endothelial cells as a novel mechanism of uric acid-induced endothelial dysfunction. J. Hypertension.28(6), 1234–1242. doi: 10.1097/HJH.0b013e328337da1d
117
ZhangC. H.HuangD. S.ShenD.ZhangL. W.MaY. J.WangY. M.et al. (2016). Association Between Serum Uric Acid Levels and Atrial Fibrillation Risk. Cell Physiol. Biochem.38 (4), 1589–1595. doi: 10.1159/000443099
118
ZhangM.SolomonD. H.DesaiR. J.KangE. H.LiuJ.NeogiT.et al. (2018). Assessment of Cardiovascular Risk in Older Patients With Gout Initiating Febuxostat Versus Allopurinol: Population-Based Cohort Study. Circulation138 (11), 1116–1126. doi: 10.1161/CIRCULATIONAHA.118.033992
119
ZhaoJ.LiuT.KorantzopoulosP.LetsasK. P.ZhangE.YangY.et al. (2016). Association between serum uric acid and atrial fibrillation recurrence following catheter ablation: A meta-analysis. Int. J. Cardiol.204, 103–105. doi: 10.1016/j.ijcard.2015.11.167
120
ZhaoY.XuL.TianD.XiaP.ZhengH.WangL.et al. (2018). Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: A meta-analysis of randomized controlled trials. Diabetes Obes. Metab.20 (2), 458–462. doi: 10.1111/dom.13101
121
ZhiL.YuzhangZ.TianliangH.HisatomeI.YamamotoT.JidongC. (2016). High Uric Acid Induces Insulin Resistance in Cardiomyocytes In Vitro and In Vivo. PloS One11 (2), e0147737. doi: 10.1371/journal.pone.0147737
122
ZinmanB.WannerC.LachinJ. M.FitchettD.BluhmkiE.HantelS.et al. (2015). Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl. J. Med.373 (22), 2117–2128. doi: 10.1056/NEJMoa1504720
Summary
Keywords
uric acid, cardiovascular disease, molecular mechanism, therapeutics, clinical prospect
Citation
Yu W and Cheng J-D (2020) Uric Acid and Cardiovascular Disease: An Update From Molecular Mechanism to Clinical Perspective. Front. Pharmacol. 11:582680. doi: 10.3389/fphar.2020.582680
Received
13 July 2020
Accepted
16 September 2020
Published
16 November 2020
Volume
11 - 2020
Edited by
Yusuf Tutar, University of Health Sciences, Turkey
Reviewed by
Claudio Borghi, University of Bologna, Italy; Carlos Alonso Escudero, University of the Bío Bío, Chile
Updates
Copyright
© 2020 Yu and Cheng.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Wei Yu, yuwei10610048@126.com; Ji-Dong Cheng, jidongcheng36@hotmail.com
This article was submitted to Cardiovascular and Smooth Muscle Pharmacology, a section of the journal Frontiers in Pharmacology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.